T1	Date 13 17	2013
T2	LIVB 181 190	pacientes
#1	AnnotatorNotes T2	C0030705; Patients; Patient or Disabled Group
T3	LIVB 306 323	Pacientes varones
#2	AnnotatorNotes T3	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group
T4	LIVB 326 333	mujeres
#3	AnnotatorNotes T4	C0043210; Woman; Population Group
T5	Age 334 360	maior ou igual que 18 años
T6	Duration 546 566	los últimos 12 meses
T7	Duration 574 594	los últimos 24 meses
T8	Duration 624 636	los 12 meses
T9	LIVB 760 769	pacientes
#4	AnnotatorNotes T9	C0030705; Patients; Patient or Disabled Group
T10	Dose 784 818	una dosis de mantenimiento estable
T12	Dose 858 875	una dosis estable
T13	LIVB 914 923	pacientes
#5	AnnotatorNotes T13	C0030705; Patients; Patient or Disabled Group
T14	Duration 1030 1041	los 3 meses
T15	Duration 1091 1104	las 3 semanas
T16	PROC 49 123	Ensayo multicéntrico, aleatorizado, a doble ciego y controlado con placebo
T17	DISO 386 389	NMO
T18	PROC 129 163	evaluar la seguridad y la eficacia
#6	AnnotatorNotes T18	C0511730; Identify product efficacy and safety issues; Health Care Activity
T19	CHEM 167 177	eculizumab
#7	AnnotatorNotes T19	C1541483; eculizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T20	DISO 195 215	neuromielitis óptica
#8	AnnotatorNotes T20	C0027873; Neuromyelitis Optica; Disease or Syndrome
T21	DISO 257 277	Neuromielitis óptica
#9	AnnotatorNotes T21	C0027873; Neuromyelitis Optica; Disease or Syndrome
T22	PROC 371 382	Diagnóstico
#10	AnnotatorNotes T22	C0011900; Diagnosis; Diagnostic Procedure
T23	DISO 392 401	trastorno
#11	AnnotatorNotes T23	C0012634; Disease; Disease or Syndrome
T24	PROC 455 458	IgG
#12	AnnotatorNotes T24	C0202087; Immunoglobulin G measurement; Laboratory Procedure
T25	PROC 518 527	protocolo
#13	AnnotatorNotes T25	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T26	PROC 710 736	Tratamiento inmunosupresor
#14	AnnotatorNotes T26	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive Procedure
T27	PROC 941 977	consentimiento informado por escrito
#15	AnnotatorNotes T27	C0811741; Obtain informed written consent; Health Care Activity
T28	CHEM 1017 1026	rituximab
#16	AnnotatorNotes T28	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T29	PROC 1055 1069	aleatorización
#17	AnnotatorNotes T29	C0034656; Randomization; Research Activity
T30	CHEM 1083 1087	IgIV
#18	AnnotatorNotes T30	C1527233; Recombinant Immune Globulin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	DISO 462 465	NMO
T32	ANAT 209 215	óptica
#19	AnnotatorNotes T32	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T33	ANAT 271 277	óptica
#20	AnnotatorNotes T33	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T34	DISO 217 220	NMO
T35	CHEM 722 736	inmunosupresor
#21	AnnotatorNotes T35	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T11	DISO 468 477	Recidivas
#22	AnnotatorNotes T11	C2825055; Recurrence (disease attribute); Pathologic Function
T36	DISO 612 620	recidiva
#23	AnnotatorNotes T36	C2825055; Recurrence (disease attribute); Pathologic Function
T37	PROC 643 662	visita de seleccion
#24	AnnotatorNotes T37	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A1	Status T11 History_of
A2	Status T36 History_of
#25	AnnotatorNotes T16	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#26	AnnotatorNotes T34	C0027873; Neuromyelitis Optica; Disease or Syndrome
#27	AnnotatorNotes T17	C0027873; Neuromyelitis Optica; Disease or Syndrome
#28	AnnotatorNotes T31	C0027873; Neuromyelitis Optica; Disease or Syndrome
R1	Experiences Arg1:T2 Arg2:T19	
R2	Experiences Arg1:T2 Arg2:T20	
R3	Location_of Arg1:T32 Arg2:T20	
R4	Location_of Arg1:T32 Arg2:T34	
T38	Observation 222 233	recidivante
#29	AnnotatorNotes T38	C2825055; Recurrence (disease attribute); Pathologic Function
R5	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T38	
R6	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T38	
R7	Experiences Arg1:T2 Arg2:T34	
R9	Location_of Arg1:T33 Arg2:T21	
R10	Has_Age Arg1:T4 Arg2:T5	
R11	Has_Age Arg1:T3 Arg2:T5	
T39	Quantifier_or_Qualifier 532 542	al menos 2
R12	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T39	
T40	Result_or_Value 431 446	Seropositividad
R13	Causes Arg1:T31 Arg2:T40	
R14	Has_Result_or_Value Arg1:T24 Arg2:T40	
R15	Overlap Arg1:T11 Arg2:T6	
R16	Overlap Arg1:T11 Arg2:T7	
T41	Quantifier_or_Qualifier 569 570	3
R17	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T41	
T42	Quantifier_or_Qualifier 601 611	al menos 1
R18	Overlap Arg1:T36 Arg2:T8	
R19	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T42	
R20	Before Arg1:T36 Arg2:T37	
T43	Result_or_Value 687 707	menor ou igual que 7
T44	CONC 682 686	EDSS
#30	AnnotatorNotes T44	C3830336; EDSS - Expanded Disability Score; Intellectual Product
R21	Has_Result_or_Value Arg1:T44 Arg2:T43	
R22	Used_for Arg1:T35 Arg2:T26	
R23	Has_Dose_or_Strength Arg1:T35 Arg2:T10	
R24	Experiences Arg1:T9 Arg2:T26	
R25	Has_Dose_or_Strength Arg1:T35 Arg2:T12	
T45	PROC 900 907	estudio
#31	AnnotatorNotes T45	C0008976; Clinical Trials; Research Activity
R26	Overlap Arg1:T26 Arg2:T45	
T46	CONC 831 841	proyección
R27	Before Arg1:T10 Arg2:T46	
R28	Overlap Arg1:T12 Arg2:T45	
R29	Overlap Arg1:T28 Arg2:T14	
R30	Before Arg1:T28 Arg2:T29	
R31	Overlap Arg1:T30 Arg2:T15	
T47	PROC 1121 1130	selección
#32	AnnotatorNotes T47	C0242802; Patient Selection; Research Activity
R32	Before Arg1:T30 Arg2:T47	
R8	Before Arg1:T11 Arg2:T37	
#33	AnnotatorNotes T46	[Selection (?)]
A3	Experiencer T13 Patient
A4	Experiencer T2 Patient
A5	Experiencer T3 Patient
A6	Experiencer T4 Patient
A7	Experiencer T9 Patient
#34	AnnotatorNotes T40	C0521143; Seropositive; Qualitative Concept
